ALLO · Allogene Therapeutics Inc
United States · RS rating 14 · As of 2026-11-03
| Price | 1.12 USD |
|---|---|
| 1-day change | +2.8% |
| RS rating (overall / 1M / 3M / 12M) | 14 / 16 / 12 / 43 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 27 / 16 / 39 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +10.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +63.4% |
| Market cap (USD) | $808.3M |